Acadia Healthcare to host intranasal ketamine trial

Franklin, Tenn.-based Acadia Healthcare will participate in a clinical trial for intranasal ketamine.

The randomized, double-blind, placebo-controlled study  is intended to evaluate the effectiveness of the drug for treating suicidal ideation and major depression, Acadia said Sept. 14. Select Acadia hospitals will be included.

Patients who exhibit specific symptoms will be eligible for enrollment in the study, Acadia said.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

Top 40 articles from the past 6 months